A further systematic review identified six potential drugs for further research into MS treatment, including Ibudilast (an anti-inflammatory drug prescribed for asthma patients), Riluzole (an inhibitor of glutamate release), Amiloride (a diuretic), Pirfenidone (a TGF-β and TNF-α synthesis inhibitor used for pulmonary fibrosis), Fluoxetine (a serotonin reuptake inhibitor used as an antidepressant), and Oxcarbazepine (a sodium channel blocker used as an anticonvulsant) [145]. Here, TNF is linked to myeloid sarcoma.